Collaborative practice agreement Sample Clauses

Collaborative practice agreement terms and provisions. A collaborative practice agreement must include the following information:
AutoNDA by SimpleDocs
Collaborative practice agreement adoption authorized. A school administrative unit or an approved private school may authorize adoption of a collaborative practice agreement for the purposes of stocking and administering epinephrine autoinjectors as provided under this section. The administration of an epinephrine autoinjector in accordance with this section is not the practice of medicine. [PL 2013, c. 526, §1 (NEW).]
Collaborative practice agreement. Under this collaborative practice agreement, UConn Health Anticoagulation Specialist(s), according to and in compliance with section 91 of Public Act 10-117 and Connecticut General Statues sSB186/File No. 213 “An ACT Concerning Collaborative Drug Therapy Management and Policies”, may design, implement, and monitor a therapeutic drug plan intended to manage anticoagulation therapies. Anticoagulation Specialists may sign patient summaries for assisted living facilities as well as orders for visiting nurses. Services offered by the Anticoagulation Specialist may include education on disease state and lifestyle modification, in addition to the drug therapy services listed above. Written educational materials and patient specific information may be provided to improve quality of care. The Anticoagulation Specialist(s) may initiate, discontinue, or adjust anticoagulation therapies in accordance with current treatment guidelines, may order laboratory tests appropriate to the disease or drug therapy. Education at office visits shall include appropriate counseling on all new medications. The results of all lab tests ordered under the protocol shall be reviewed and managed by the Anticoagulation Specialist(s) to assess efficacy of treatment and necessity for medication and/or therapeutic lifestyle change. Lab results will be relayed to clinic patients by a patient-specific predetermined method which may include face-to-face encounter, scheduled secure telephone/video visit, or written communication. Any lab outliers that require further investigation will be sent to the referring provider and/or PCP as appropriate and the patient will be told to contact that LIP immediately. If the LIP is not available, the patient will be sent to the UConn Health Emergency Department. A patient whose drug therapy is managed under this agreement must have established care with a provider within UConn Health and all aspects of the patient’s anticoagulation medication management will be followed in collaboration with the patient’s referring provider (or primary care as necessary). In addition, the patient must be seen by their UConn Health provider at least once per year, in addition to which cases may be reviewed with clinic medical directors as needed. All issues outside of the scope of anticoagulation medication management shall be referred to the patient’s primary care provider, daily supervising LIP or medical director(s). The Anticoagulation Specialist(s) will assure documentati...
Collaborative practice agreement adoption authorized. A school administrative unit or an approved private school may authorize adoption of a collaborative practice agreement for the purposes of stocking, possessing and administering naloxone hydrochloride as provided under this section. The administration of naloxone hydrochloride in accordance with this section is not the practice of medicine. [PL 2021, c. 115, §1 (NEW).]
Collaborative practice agreement. Under this collaborative practice agreement, UConn HealthXxxx Xxxxxxx Hospital Pharmacists, according to and in compliance with Section 91 of Public Act 10-7 and Connecticut General Statutes sec 20-631 “An Act Concerning Collaborative Practice Between Physicians and Pharmacists”, may design, implement, and monitor a therapeutic drug plan intended to manage IV Vancomycin therapy upon receipt of an order from the licensed provider to the Pharmacist for IV Vancomycin dosing. The specific services provided by the Pharmacists and the methods for providing these services are described in detail in this protocol document
Collaborative practice agreement. NOTICE OF INTENT advanced practice registered nurse by the. Requirements for Provider Type 09 Certified Registered. NYS Nursing Practice Information Collaborative Practice. 4723 8 04 Standard care arrangement for a certified nurse. How Does Nurse Practitioner Authority Vary By State. NURSE PROTOCOL AGREEMENT Georgia. Nurse practitioners can practice without physician. IMPORTANT Read the Complete Instructions on the Reverse. Collaborative Practice Agreement Protocols. Should a Written Collaborative Practice Agreement with a. Prescriptive Authority IL Society for Advanced Practice. Nurse Practitioner Jobs Patient Population. ADVANCED PRACTICE REGISTERED NURSE COLLABORATIVE AGREEMENTS.
Collaborative practice agreement. SSM Physician
AutoNDA by SimpleDocs
Collaborative practice agreement. This collaborative practice agreement is an expanded scope of practice of the pharmacist identified herein. Upon approval of this agreement by the IWK Medical Advisory Committee, the Nova Scotia College of Pharmacists will approve the practice setting prior to the Collaborative Practice Agreement taking effect under section 3f of the Pharmacy Practice Regulations.

Related to Collaborative practice agreement

  • Development Agreement As soon as reasonably practicable following the ISO’s selection of a transmission Short-Term Reliability Process Solution, the ISO shall tender to the Developer that proposed the selected transmission Short-Term Reliability Process Solution a draft Development Agreement, with draft appendices completed by the ISO to the extent practicable, for review and completion by the Developer. The draft Development Agreement shall be in the form of the ISO’s Commission-approved Development Agreement for its Reliability Planning Process, which is in Appendix C in Section 31.7 of Attachment Y of the ISO OATT, as amended by the ISO to reflect the Short-Term Reliability Process. The ISO and the Developer shall finalize the Development Agreement and appendices as soon as reasonably practicable after the ISO’s tendering of the draft Development Agreement. For purposes of finalizing the Development Agreement, the ISO and Developer shall develop the description and dates for the milestones necessary to develop and construct the selected project by the required in-service date identified in the STAR or Generator Deactivation Assessment, including the milestones for obtaining all necessary authorizations. Any milestone that requires action by a Connecting Transmission Owner or Affected System Operator identified pursuant to Attachment P of the ISO OATT to complete must be included as an Advisory Milestone, as that term is defined in the Development Agreement. If the ISO or the Developer determines that negotiations are at an impasse, the ISO may file the Development Agreement in unexecuted form with the Commission on its own, or following the Developer’s request in writing that the agreement be filed unexecuted. If the Development Agreement is executed by both parties, the ISO shall file the agreement with the Commission for its acceptance within ten (10) Business Days after the execution of the Development Agreement by both parties. If the Developer requests that the Development Agreement be filed unexecuted, the ISO shall file the agreement at the Commission within ten (10) Business Days of receipt of the request from the Developer. The ISO will draft, to the extent practicable, the portions of the Development Agreement and appendices that are in dispute and will provide an explanation to the Commission of any matters as to which the parties disagree. The Developer will provide in a separate filing any comments that it has on the unexecuted agreement, including any alternative positions it may have with respect to the disputed provisions. Upon the ISO’s and the Developer’s execution of the Development Agreement or the ISO’s filing of an unexecuted Development Agreement with the Commission, the ISO and the Developer shall perform their respective obligations in accordance with the terms of the Development Agreement that are not in dispute, subject to modification by the Commission. The Connecting Transmission Owner(s) and Affected System Operator(s) that are identified in Attachment P of the ISO OATT in connection with the selected transmission Short-Term Reliability Process Solution shall act in good faith in timely performing their obligations that are required for the Developer to satisfy its obligations under the Development Agreement.

  • License Agreement The Trust shall have the non-exclusive right to use the name "Invesco" to designate any current or future series of shares only so long as Invesco Advisers, Inc. serves as investment manager or adviser to the Trust with respect to such series of shares.

  • Our Agreement You, the Insured/ Insured Person, and We, the Company, agree

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date.

  • Software License Agreement 1) Customers acquiring software licenses under the Contract shall hold, use and operate such software subject to compliance with the Software License Agreement set forth in Appendix D of this Contract. No changes to the Software License Agreement terms and conditions may be made unless previously agreed to between Vendor and DIR. Customers may not add, delete or alter any of the language in Appendix D; provided however, that a Customer and Vendor may agree to additional terms and conditions that do not diminish a term or condition in the Software License Agreement, or in any manner lessen the rights or protections of Customer or the responsibilities or liabilities of Vendor. Order Fulfiller shall make the Software License Agreement terms and conditions available to all Customers at all times.

  • Cooperation Agreement At the Closing, PCC and Buyer shall, and PCC shall cause PCC Parent to, execute and deliver the Cooperation Agreement pursuant to which Buyer, PCC Parent and PCC shall provide each other certain information and other assistance in connection with the collection, administration and/or satisfaction of certain of the Retained Liabilities.

  • Promotion of Agreement It is agreed that Vendor will encourage all eligible entities to purchase from the TIPS Program. Encouraging entities to purchase directly from the Vendor and not through TIPS Agreement is a violation of the terms and conditions of this Agreement and will result in removal of the Vendor from the TIPS Program.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • End User License Agreement This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. xxxx://xxxxxxxxxxxxxxx.xxx/licenses/by-nc-nd/3.0/ You are free to: Share: to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!